Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Malamut

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Postgraduate Medicine|November 15, 2015
Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulationsMaciej Gasior, Mary Bond, Richard Malamut
Journal of Opioid Management|May 20, 2016
Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potentialMartin E Hale, Yuju Ma, Richard Malamut
Cleveland Clinic Journal of Medicine|June 3, 2005
Diabetic retinopathy: treating systemic conditions aggressively can save sightStephen H Sinclair, Richard Malamut, Cherie Delvecchio, et al.
Journal of Opioid Management|January 6, 2016
Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back painMartin E Hale, Thomas R Zimmerman, Eli Eyal, et al.
Pain Practice : the Official Journal of World Institute of Pain|February 10, 2016
Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic PainMartin E Hale, Thomas R Zimmerman, Yuju Ma, et al.
Journal of Opioid Management|November 5, 2015
Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic painMartin E Hale, Thomas R Zimmerman, Yuju Ma, et al.
Journal of Pain Research|September 24, 2015
Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back painMartin E Hale, Charles Laudadio, Ronghua Yang, et al.
Pain Management|April 7, 2016
Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer painMartin E Hale, Derek Moe, Mary Bond, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|November 3, 2011
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scaleHoracio Kaufmann, Richard Malamut, Lucy Norcliffe-Kaufmann, et al.
Muscle & Nerve|July 9, 2005
Usefulness of electrodiagnostic techniques in the evaluation of suspected tarsal tunnel syndrome: an evidence-based reviewAtul T Patel, Kenneth Gaines, Richard Malamut, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Postgraduate Medicine|November 15, 2015
Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulationsMaciej Gasior, Mary Bond, Richard Malamut
Journal of Opioid Management|May 20, 2016
Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potentialMartin E Hale, Yuju Ma, Richard Malamut
Cleveland Clinic Journal of Medicine|June 3, 2005
Diabetic retinopathy: treating systemic conditions aggressively can save sightStephen H Sinclair, Richard Malamut, Cherie Delvecchio, et al.
Journal of Opioid Management|January 6, 2016
Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back painMartin E Hale, Thomas R Zimmerman, Eli Eyal, et al.
Pain Practice : the Official Journal of World Institute of Pain|February 10, 2016
Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic PainMartin E Hale, Thomas R Zimmerman, Yuju Ma, et al.
Journal of Opioid Management|November 5, 2015
Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic painMartin E Hale, Thomas R Zimmerman, Yuju Ma, et al.
Journal of Pain Research|September 24, 2015
Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back painMartin E Hale, Charles Laudadio, Ronghua Yang, et al.
Pain Management|April 7, 2016
Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer painMartin E Hale, Derek Moe, Mary Bond, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|November 3, 2011
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scaleHoracio Kaufmann, Richard Malamut, Lucy Norcliffe-Kaufmann, et al.
Muscle & Nerve|July 9, 2005
Usefulness of electrodiagnostic techniques in the evaluation of suspected tarsal tunnel syndrome: an evidence-based reviewAtul T Patel, Kenneth Gaines, Richard Malamut, et al.
Pageof 3